GSK-PAR 29060/627

A 12-Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Tolerability of Paroxetine in Patients Suffering from Post-traumatic Stress Disorder (PTSD)
PAR 29060/627
Post-Traumatic Stress Disorder
Phase 3
The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset, an annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
December 2014